Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says

Sarepta Therapeutics' (SRPT) Elevidys is put under a "little" pressure on Regenxbio's (RGNX) positive trial data in Duchenne muscular dystrophy, Wedbush Securities said in a note Friday.

The note pointed to statistically significant correlation between microdystrophin expression and functional improvement in the trial of RGX-202, and should benefit all microdystrophin gene therapy programs/products.

"We see no other big impact on Elevidys," it said. "We do not believe that the relatively small patient number in RGNX's study allows for a fair comparison of microdystrophin expression."

The report also said the regulatory pathway for RGX-202 remains to be defined.

Wedbush kept its outperform rating and a $35 price target.

Price: $18.12, Change: $-0.56, Percent Change: -3.00%

AeroVironment's Position in Unmanned Aircraft Market Positive, but Faces Near-Term Headwinds, RBC Says

AeroVironment's (AVAV) position in the unmanned aerial systems market is likable but it faces near-term risks around visibility into 2026 US Department of War budget, geopolitical de-escalation, and the potential for mid-term election risk, RBC Capital Markets said in a research report emailed Friday.The company has recently struggled with execution, resulting in underperformance, but management remains confident in its Q4 guidance, which can be a positive catalyst, analysts wrote.Beyond Q4, catalysts include the company's confidence in its enduring-high energy laser and long-range reconnaissance contract opportunities, according to the note.The brokerage said it reiterated its outperform rating on the stock and price target of $250 per share.Price: $157.73, Change: $-7.54, Percent Change: -4.56%

$AVAV

JBS Likely to See Improving Earnings Momentum, Morgan Stanley Says

JBS (JBS) is likely to see improving earnings momentum, a valuation angle, and free cash flow buffer despite a weak start to the year, Morgan Stanley said in a note Friday.US Beef cycle remains challenging and Q2 industry margins appear weaker through May, but there are better signs into June and July, according to the note.The brokerage said it cut its 2026 EBITDA forecast by 7% after Q1 miss, but softer PPC estimates are likely related to temporary headwinds, and not structural issues.For the company's poultry producer, Morgan Stanley lowered its full-year EBITDA estimate by 9% but expects improvement in Q2 due to favorable seasonality and lower impacts from transient disruptions, according to the note.Morgan Stanley adjusted its price target to $19 per share from $20.50, while reiterating its overweight rating on the stock.Price: $13.62, Change: $-0.37, Percent Change: -2.61%

$JBS

Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says

Related Articles

AeroVironment's Position in Unmanned Aircraft Market Positive, but Faces Near-Term Headwinds, RBC Says

JBS Likely to See Improving Earnings Momentum, Morgan Stanley Says

Tyson Foods' Settlement Agreement in Beef Antitrust Case Gets Preliminary Approval